Mirati Therapeutics CEO Charles Baum's 2019 pay jumps 74% to $8.5M
Mirati Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 17, 2020
Mirati Therapeutics reported fiscal year 2019 executive compensation information on April 17, 2020.
In 2019, five executives at Mirati Therapeutics received on average a compensation package of $4.3M, a 61% increase compared to previous year.
Average pay of disclosed executives at Mirati Therapeutics
Charles M. Baum, Chief Executive Officer, received $8.5M in total, which increased by 74% compared to 2018. 88% of Baum's compensation, or $7.5M, was in option awards. Baum also received $411K in non-equity incentive plan, $597K in salary, as well as $2.5K in other compensation.
For fiscal year 2019, the median employee pay was $588,168 at Mirati Therapeutics. Therefore, the ratio of Charles M. Baum's pay to the median employee pay was 14 to one.
James Christensen, Chief Scientific Officer, received a compensation package of $3.3M, which increased by 3% compared to previous year. 80% of the compensation package, or $2.6M, was in option awards.
Isan Chen, Executive Vice President and Chief Medical and Development Officer, earned $3.3M in 2019, a 92% increase compared to previous year.
Jamie A. Donadio, Chief Financial Officer, received $3.2M in 2019, which increases by 97% compared to 2018.
Chris LeMasters, Former Executive Vice President and Chief Business Officer, earned $3.2M in 2019, a 65% increase compared to previous year.
Related executives
Charles Baum
Mirati Therapeutics
Chief Executive Officer
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
James Christensen
Mirati Therapeutics
Chief Scientific Officer
Jamie Donadio
Mirati Therapeutics
Chief Financial Officer
Chris LeMasters
Mirati Therapeutics
Former Executive Vice President and Chief Business Officer
You may also like
Source: SEC filing on April 17, 2020.